Consequently, we sought to divide the LUAD cohort into four groups: FAT3 and LRP1B co-mutation group (FAT3+/LRP1B+), FAT3 mutation only group (FAT3+), LRP1B mutation only group (LRP1B+), and FAT3 and LRP1B double wild-type group (WT), to analyze the relationship between mutation status and demographic and clinicopathological characteristics of lung adenocarcinoma patients (Table 1). This evidence concerns the gene LRP1B and lung adenocarcinoma.